Abstract
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.
Highlights
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men,[1] as well as congestive heart failure,[2] chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases,[3,4], diabetes[5] and various other conditions.[6]
The results of this study show that SSD-associated pulmonary arterial hypertension was not responsive to additional sildenafil therapy, beneficial effects were found in the idiopathic pulmonary arterial hypertension group after failing bosentan monotherapy
PDE5 inhibitors have contributed to our knowledge of the pathophysiology of pulmonary vascular disease, and have become the leading oral therapy for pulmonary hypertension worldwide and in particular in the developing word
Summary
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men,[1] as well as congestive heart failure,[2] chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases,[3,4], diabetes[5] and various other conditions.[6]. Treatment with single agents remains far from satisfactory though it may maximize the therapeutic benefits such as symptom control and increased rate of survival.[145,146,147] Most current clinical practice guidelines recommend combination therapy in functional classes III and IV if there is no improvement or if there is deterioration.[148,149,150,151] The REVEAL registry demonstrated that nearly 50% of patients with pulmonary arterial hypertension received combination treatment.[152] The majority of combination therapy involves PDE5 inhibitors.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
